CTLA4 and neoplasm: We sought to test whether activation of TLR9 through intra-tumoral injection in the B16-Ova melanoma model could potentiate systemic, sterilizing anti-tumor immunity in conjunction with blockade of the T cell immune checkpoint receptor CTLA-4.